| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
856,317 |
| 52
Week Range: |
$206.39 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
19,405 |
420,533 |
| Total Sell Value |
$0 |
$0 |
$4,136,219 |
$77,127,618 |
| Total People Sold |
0 |
0 |
2 |
8 |
| Total Sell Transactions |
0 |
0 |
2 |
58 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mclaughlin John Peter |
Director |
– • – |
2016-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,700 |
39,400 |
|
- |
|
| Gryska David W |
Director |
– • – |
2016-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,700 |
27,650 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2016-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
3,700 |
24,805 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-05-20 |
4 |
A |
$38.82 |
$287,268 |
I/I |
7,400 |
38,787,087 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-05-17 |
4 |
AS |
$35.16 |
$267,849 |
D/D |
(7,618) |
556,115 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-05-17 |
4 |
OE |
$4.45 |
$33,900 |
D/D |
7,618 |
563,733 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-04-25 |
4 |
AS |
$40.00 |
$32,000 |
D/D |
(800) |
556,115 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-04-25 |
4 |
OE |
$10.20 |
$8,160 |
D/D |
800 |
556,915 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-04-05 |
4 |
AS |
$36.12 |
$275,162 |
D/D |
(7,618) |
556,115 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-04-05 |
4 |
OE |
$4.45 |
$33,900 |
D/D |
7,618 |
563,733 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-03-22 |
4 |
AS |
$35.69 |
$391,317 |
D/D |
(10,954) |
556,115 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-03-22 |
4 |
OE |
$4.45 |
$48,745 |
D/D |
10,954 |
567,069 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-03-21 |
4 |
AS |
$35.01 |
$149,913 |
D/D |
(4,282) |
556,115 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-03-21 |
4 |
OE |
$4.45 |
$19,055 |
D/D |
4,282 |
560,397 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-17 |
4 |
B |
$31.73 |
$3,951,304 |
I/I |
124,065 |
38,783,387 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-16 |
4 |
B |
$31.50 |
$18,084,600 |
I/I |
569,203 |
38,671,506 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-15 |
4 |
B |
$31.50 |
$21,210,834 |
I/I |
661,093 |
38,158,204 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-14 |
4 |
B |
$33.77 |
$4,016,519 |
I/I |
118,941 |
37,562,036 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-11 |
4 |
B |
$32.34 |
$6,480,738 |
I/I |
195,765 |
37,454,776 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-10 |
4 |
B |
$32.30 |
$9,386,567 |
I/I |
290,231 |
37,278,782 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-09 |
4 |
B |
$31.15 |
$6,683,985 |
I/I |
208,670 |
37,017,863 |
2.25 |
- |
|
| Welch Daniel G |
Director |
– • – |
2016-03-08 |
4 |
OE |
$9.82 |
$245,500 |
D/D |
25,000 |
41,819 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-08 |
4 |
B |
$0.00 |
$0 |
I/I |
153,200 |
36,830,268 |
2.17 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-08 |
4 |
OE |
$4.18 |
$83,600 |
I/I |
20,000 |
36,692,540 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-03-07 |
4 |
B |
$33.68 |
$2,063,918 |
I/I |
61,265 |
36,682,540 |
2.25 |
- |
|
1805 Records found
|
|
Page 32 of 73 |
|
|
